Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Study Identifier:
ALXN1210-NMO-317
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Jun 2022 - Mar 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Jun 2022 - Mar 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
Trial Locations
Location
Status
Location
Research Site
Washington, District of Columbia, United States, 20010
Status
Recruiting
Location
Research Site
Miami, Florida, United States, 33136
Status
Recruiting
Location
Research Site
Boston, Massachusetts, United States, 02114
Status
Recruiting
Location
Research Site
Saint Louis, Missouri, United States, 63110
Status
Withdrawn
Location
Research Site
Durham, North Carolina, United States, 27705
Status
Recruiting
Location
Research Site
Philadelphia, Pennsylvania, United States, 19104
Status
Recruiting